Ver Investigador - - Prisma - Unidad de Bibliometría

Daniel José Garcia Dominguez

Plan Propio-Acceso
Área de conocimiento: Bioquímica y Biología Molecular
Departamento: Bioquímica Médica y Biología Molecular e Inmunología
Grupo: Sin Grupo
Tipo Año Título Fuente
Artículo2024 Cancer nano-immunotherapy: the novel and promising weapon to fight cancer INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Artículo2024 CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma FRONTIERS IN IMMUNOLOGY
Revisión2023 Defining the emergence of new immunotherapy approaches in breast cancer: role of myeloid-derived suppressor cells INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Capítulo2023 Knowing the myeloid-derived suppressor cells: another enemy of sarcomas patients Myeloid-derived suppressor cells
Artículo2022 Ewing sarcoma meets epigenetics, immunology and nanomedicine: moving forward into novel therapeutic strategies. CANCERS
Artículo2022 Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis CLINICAL CANCER RESEARCH
Artículo2022 Obesity and risk for lymphoma: possible role of leptin. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Artículo2022 Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1 ONCOGENE
Revisión2022 Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics CANCERS
Artículo2021 Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma ONCOGENE
Revisión2021 The bitter side of epigenetics: variability and resistance to chemotherapy Epigenomics
Artículo2020 An inducible ectopic expression system of EWSR1-FLI1 as a tool for understanding Ewing sarcoma oncogenesis PLOS ONE
Artículo2020 RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis SCIENCE ADVANCES
Revisión2020 Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials FRONTIERS IN GENETICS
Artículo2020 Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution JOURNAL OF CONTROLLED RELEASE
Artículo2018 The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma ONCOTARGET
Artículo2017 HMGA2 overexpression predicts relapse susceptibility of blastemal Wilms tumor patients ONCOTARGET
Corrección2017 Inhibition of IRE1 alpha-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia (vol 8, pg 11173, 2017) ONCOTARGET
Resumen congreso2017 MDR3 and MRP1 Overexpression Are Poor Prognosis Markers in Wilms Tumor Patients After SIOP-93-01 Standard Treatment Protocol LABORATORY INVESTIGATION
Artículo2017 Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients ONCOTARGET
Revisión2014 Innovative Therapies in Ewing Sarcoma Advances in Anatomic Pathology
Artículo2013 WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells ONCOGENE
Artículo2012 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma ONCOGENE
Artículo2011 Stabilization of Dll1 mRNA by Elavl1/HuR in neuroepithelial cells undergoing mitosis MOLECULAR BIOLOGY OF THE CELL
Revisión2010 The Clinical Relevance of Molecular Genetics in Soft Tissue Sarcomas Advances in Anatomic Pathology

Proyectos de Investigación

Fecha de inicio Fecha de fin Rol Denominación Agencia financiadora
01/01/2020 31/12/2022 Investigador/a Study of the prognostic and functional role of mesenchymal stem cell markers Endoglin and ALCAM in the disease progression of Clear cell sarcomas (CCS) and Desmoplastic small Round cell tumours (DSRCT) (P18-RT-735) Junta de Andalucía (Consejería de Economía y Conocimiento) (Autonómico)
El investigador no tiene ningún resultado de investigación asociado